Large-scale testing (Phase 3)UnknownNCT02409199What this trial is testingApatinib Versus Docetaxol Patients With Advanced Gastric CancerWho this might be right forGastric Carcinoma Shanghai Zhongshan Hospital 66
Testing effectiveness (Phase 2)Study completedNCT02689284What this trial is testingCombination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerWho this might be right forGastric CancerStomach CancerEsophageal Cancer MacroGenics 95
Not applicableLooking for participantsNCT06846996What this trial is testingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaWho this might be right forHER2-positive Gastric CancerHER2-positive Gastroesophageal Junction Daiichi Sankyo 260
Testing effectiveness (Phase 2)Ended earlyNCT00256321What this trial is testingCelecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction CarcinomaWho this might be right forGastric CarcinomaGastroesophageal Junction Carcinoma University of California, Irvine 4
Testing effectiveness (Phase 2)Looking for participantsNCT05640609What this trial is testingCapeox Regimen Combined With Sintilimab and Bevacizumab for Gastric CancerWho this might be right forStomach Neoplasm West China Hospital 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT06116136What this trial is testingEvaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Who this might be right forMSI-H/dMMR Gastroesophageal-junction CancerMSI-H/dMMR Gastric Cancer Servier Bio-Innovation LLC 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT04847466What this trial is testingImmunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerWho this might be right forGastroesophageal Junction (GEJ) CancersAdvanced HNSCC National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT01611857What this trial is testingPhase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or StomachWho this might be right forMalignant Solid TumourGastroesophageal Cancer SCRI Development Innovations, LLC 49
Large-scale testing (Phase 3)Active Not RecruitingNCT04950322What this trial is testingA Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal CancerWho this might be right forGastric or Gastroesophageal Junction Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 737
Large-scale testing (Phase 3)Study completedNCT00680901What this trial is testingLOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibWho this might be right forNeoplasms, Gastrointestinal Tract Novartis Pharmaceuticals 545
Testing effectiveness (Phase 2)Looking for participantsNCT07315854What this trial is testingIparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerWho this might be right forGastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more Beijing Friendship Hospital 32
Early research (Phase 1)Study completedNCT04805307What this trial is testingSafety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901Who this might be right forAdvanced Solid TumorGastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)Pancreatic Cancer Keymed Biosciences Co.Ltd 176
Testing effectiveness (Phase 2)Study completedNCT00940225What this trial is testingStudy of Cabozantinib (XL184) in Adults With Advanced MalignanciesWho this might be right forSolid TumorsCancer Exelixis 730
Testing effectiveness (Phase 2)Study completedNCT00780494What this trial is testingPh II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric CarcinomaWho this might be right forStomach CancerGastric (Stomach) CancerNeoplasm of Cardioesophageal Junction+1 more Stanford University 35
Large-scale testing (Phase 3)Study completedNCT03675737What this trial is testingPembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)Who this might be right forStomach Neoplasms Merck Sharp & Dohme LLC 1,579
Large-scale testing (Phase 3)UnknownNCT01015339What this trial is testingPaclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionWho this might be right forAdvanced Gastric Cancer Peking University 320
Not applicableUnknownNCT04915807What this trial is testingReal-world Data (RWD) of Ramucirumab Plus PaclitaxelWho this might be right forGastric CancerGastroesophageal Junction Adenocarcinoma Hallym University Medical Center 222
Testing effectiveness (Phase 2)Looking for participantsNCT05086692What this trial is testingA Beta-only IL-2 ImmunoTherapY StudyWho this might be right forAdvanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)UnknownNCT04263870What this trial is testingConversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionWho this might be right forGastroesophageal Junction AdenocarcinomaStomach AdenocarcinomaLocally Advanced Unresectable Gastric Adenocarcinoma+1 more Sichuan University 36
Testing effectiveness (Phase 2)Study completedNCT03083613What this trial is testingRaltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction AdenocarcinomaWho this might be right forGastric CancerGastroesophageal Junction Adenocarcinoma Chinese Academy of Medical Sciences 41